Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With $30M In Hand, Zosano Hopes Its Osteoporosis Patch Will Compete With Forteo

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite a long list of potential therapeutic uses for its transdermal patch technology, privately held biotech seeks direct competition in osteoporosis anabolic therapy space.
Advertisement

Related Content

Deal Watch: Sanofi And Evotec Negotiate Alliance Aimed At Improving Drug Discovery
Amgen's Denosumab Trumps Zometa with Top-Line Results for Cancer Bone Complications
After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone

Topics

Advertisement
UsernamePublicRestriction

Register

PS069817

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel